Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
999 Leser
Artikel bewerten:
(2)

Atos International: Eviden takes quantum computing application development to the next level with its new Qaptiva offering

Paris, France - May 11, 2023-Eviden, the Atosbusiness leading in digital, cloud, big data and security, today launches QaptivaTM, its new Quantum Computing offering to enable real world application development and usage, using best-of-breed quantum computing technologies.

While some vertical markets are starting to show readiness to use quantum computing for problems addressed today by supercomputers, the customer's focus is shifting from learning to developing and consuming quantum computing real life applications.

With QaptivaTM, Eviden is embracing this new era by enabling a rich Software and Hardware partner ecosystem to use the QaptivaTM Application development platform, offering corporate customers solutions to facilitate the development of tangible quantum applications, and run them in as-a-service or on premises modes.

Capitalizing on Eviden's strong experience in hybrid computing, QaptivaTM will help enterprises, organizations, and research centers worldwide to harness the power of quantum computing and take application development to the next level, to solve complex business and scientific challenges.

Unlocking value from quantum computing with all-in-one offering

Developing real-life applications using quantum computing-based paradigms requires building specialized, problem-solving-oriented set of software libraries for developers to use their own domain specific objects without being quantum physics specialists.

As such, Eviden is expanding itspartners ecosystem to provide developers with a wide choice of quantum software libraries to increase value for its customers while offering different choices of hardware. To support the evolution of quantum software, the team has partnered with innovation-driven Quantum players like ColibrITD, QuantFI, QubitSoft, Qubit Pharmaceuticals, QuRISK and Multiverse Computing to integrate them in QaptivaTM and to address industry-specific use cases related to automotive, defense, energy, finance, life science and retail. For quantum computing hardware, after the signature of an agreement with its forward-thinking partner IQM Quantum Computers in 2022, Eviden is now also collaborating with French technology leaders Quandela and Pasqal for joint commercial offers.

QaptivaTM offers all-in-one capabilities and a best-in-class development environment to write code once and seamlessly run it on different quantum hardware, either on-premises or through the cloud. Designed to encompass in one place all quantum technologies provided by QaptivaTM software partners, this platform provides developers, researchers, and scientists with all the necessary tools and resources (libraries, connectors, emulators, and compilers) to program, optimize, compile, emulate, and run code on a Quantum Processing Unit (QPU), delivering tangible results very rapidly without waiting for Large Scale Quantum (LSQ).

In addition to a complete and simplified quantum-application development environment, QaptivaTM also offers emulation capabilities to perform perfect advanced emulations with different noise models, up to 41 logical Qubits. The offer leverages the technology available in the QaptivaTM 800, the new generation of the previously known "Atos Quantum Learning Machine".

For application development and emulation, QaptivaTM supports all the most widely used quantum programming paradigms (gate-based, annealing, and analog) and other technologies such as photonic quantum computing.

QaptivaTM includes a complete quantum computingconsulting practice, from training to application development to help enterprises, organizations and research centers understand, and identify real use cases, and develop their future production-ready QC-based solutions.

"Capitalizing on our strong experience in quantum computing, we are pleased to launch our new offering, QaptivaTM, to simplify the development of quantum applications with an all-in-one offering for enterprises while pursuing our research and development efforts to make Hybrid Computing a reality for research centers. By providing greater choice in deployment, whether on-premises or in the cloud, and computing flexibility, QaptivaTMdemocratizes access to quantum computing." said Dr Cédric Bourrasset, Global Head of HPC-AI and Quantum Computing,Eviden, Atos Group.

"Eviden is a global leader in Quantum Computing and with the launch of QAPTIVA, a complete as-a-service offer focused on applications development, Eviden is on the right path toward rapid innovation and adoption of Quantum Computing for enterprises and businesses. This allows Eviden to acquire new capabilities, extend its solutions to address new markets, and meet customer needs. With their proven expertise in High Performance Computing (HPC), Eviden can support the adoption of hybridization to combine quantum, traditional HPC and AI at scale. Eviden has all the critical elements and potential to contribute meaningfully to the future of Quantum Computing," said Bob Sorensen, Chief Analyst for Quantum Computing, Hyperion Research

***

About Eviden1

Evidendesigns the scope composed of Atos' digital, cloud, big data and security business lines. It will be a global leader in data-driven, trusted and sustainable digital transformation. As a next generation digital business with worldwide leading positions in digital, cloud, data, advanced computing and security, it brings deep expertise for all industries in more than 53 countries. By uniting unique high-end technologies across the full digital continuum with 57,000 world-class talents, Eviden expands the possibilities of technologies for enterprises and public authorities, helping them to build their digital future. Eviden is an Atos Group business with an annual revenue of c. € 5 billion.

About Atos

Atosis a global leader in digital transformation with 111,000 employees and annual revenue of c. € 11 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea), and listed on Euronext Paris.

The purpose of Atosis to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Press contact

Constance Arnoux - constance.arnoux@atos.net- +33 (0)6 44 12 16 35


1Eviden business is operated through the following brands: Agarik, Alia Consulting, AppCentrica, ATHEA, Atos Syntel, Bull, Cloudamize, Cloudreach, Cryptovision, DataSentics, digital.security, Eagle Creek, EcoAct, Edifixio, Energy4U, Engage ESM, Forensik, IDEAL GRP, IDnomic, In Fidem, Ipsotek, Maven Wave, Miner & Kasch, Motiv, Nimbix, Processia, Profit4SF, science+computing, SEC Consult, Visual BI, Worldgrid, X-Perion, zData
Legal Mentions Eviden and the Eviden logo are trademarks of Bull S.A.S © 2023 Bull S.A.S.

Attachment

  • PR - Eviden takes quantum computing application development to the next level with its new Qaptiva offering (https://ml-eu.globenewswire.com/Resource/Download/b5a4256d-fee7-4931-8565-36f7ffa1925e)

© 2023 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.